Abstract | AIMS: METHODS AND RESULTS: We studied patients randomized to aspirin or aspirin plus clopidogrel in the ACTIVE trials, comparing the thromboembolic rate in the peri- cardioversion period (30 days before until 30 days after) to the rate during follow-up, remote from cardioversion. Among 962 patients, the 30-day thromboembolic rate remote from cardioversion was 0.16%; while it was 0.73% in the peri- cardioversion period [hazard ratio (HR) 4.1, 95% confidence interval (CI) 2.1-7.9]. The 30-day thromboembolic rates in the periods immediately before and after cardioversion were 0.47% and 0.96%, respectively (HR 2.2, 95% CI 0.7-7.1). Heart failure (HF) hospitalization increased in the peri- cardioversion period (HR 11.5, 95% CI 6.8-19.4). Compared to baseline, the thromboembolic rate in the 30 days following cardioversion was increased both in patients who received oral anticoagulation or a transoesophageal echocardiogram prior to cardioversion (HR 7.9, 95% CI 2.8-22.4) and in those who did not (HR 4.8, 95% CI 1.6-14.9) (interaction P = 0.2); the risk was also increased with successful (HR 4.5; 95% CI 2.0-10.5) and unsuccessful (HR 10.2; 95% CI 2.3-44.9) cardioversion. CONCLUSIONS:
|
Authors | William F McIntyre, Stuart J Connolly, Jia Wang, Simona Masiero, Alexander P Benz, David Conen, Jorge A Wong, Heather Beresh, Jeff S Healey |
Journal | European heart journal
(Eur Heart J)
Vol. 40
Issue 36
Pg. 3026-3032
(09 21 2019)
ISSN: 1522-9645 [Electronic] England |
PMID | 31377776
(Publication Type: Journal Article)
|
Copyright | Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2019. For permissions, please email: [email protected]. |
Chemical References |
- Platelet Aggregation Inhibitors
- Clopidogrel
- Aspirin
|
Topics |
- Aged
- Aspirin
(therapeutic use)
- Atrial Fibrillation
(therapy)
- Clopidogrel
(therapeutic use)
- Electric Countershock
- Female
- Follow-Up Studies
- Heart Failure
(epidemiology)
- Hospitalization
(statistics & numerical data)
- Humans
- Male
- Platelet Aggregation Inhibitors
(therapeutic use)
- Randomized Controlled Trials as Topic
- Risk
- Thromboembolism
(epidemiology)
|